Human leukocyte antigen class II complexed with conserved HIV-1 peptides (HIVconsv-HLA-II)

The HIVconsv-derived peptides bound to human MHC class II peptide-binding grooves represent a critical immunological complex for the development of T-cell-based HIV vaccines. HIVconsv is a chimeric immunogen consisting of the 14 most conserved regions of the HIV-1 proteome, designed to overcome the high genetic variability of the virus by targeting regions where mutations are likely to incur a high fitness cost (Létourneau et al., 2007, PLoS ONE). When these conserved peptides are processed and presented by Major Histocompatibility Complex (MHC) class II molecules (HLA-DR, -DQ, and -DP), they are recognized by the T-cell receptors (TCRs) of CD4+ T helper cells. This interaction is essential for orchestrating a robust immune response, including the provision of help for B-cell antibody production and the maintenance of CD8+ cytotoxic T-cell memory (Hanke, 2019, Expert Review of Vaccines). Therapeutic interventions, such as the ChAdOx1.HIVconsv and MVA.HIVconsv vaccines, aim to generate this complex in vivo to prime and boost the immune system against conserved viral targets (Borthwick et al., 2014, Molecular Therapy). Understanding the binding affinity and presentation of these peptides across diverse HLA alleles is vital for ensuring broad population coverage and vaccine efficacy (Ondondo et al., 2016, Scientific Reports).

Other names

HIVconsv-derived peptide-MHC II complexHLA-DR/HIVconsv peptide complexConserved HIV-1 immunogen peptides presented by MHC IIpMHC II complex (HIVconsv)

Induction of CD4+ T-cell responses through the presentation of conserved viral epitopes on MHC class II molecules to stimulate cellular immunity and provide help for CD8+ T-cell and B-cell responses.